The Food and Drug Administration is announcing the availability of a final guidance for industry entitled “E6(R3) Good Clinical Practice.” This revision incorporates flexible, risk-based approaches and embraces innovations in trial design, conduct, and technology.
Similar Posts
Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Drug Shortage Mitigation Efforts
The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March 27, 2020 to aid response efforts and ease the economic impact of COVID-19.The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug DevelopmentGO Raw LLC. Expands Voluntary Recall of Quest Diet Cat Food Products Due to Low Thiamine Levels and Enacts Stop Sale of All Quest Products
Cottonwood Heights, Utah (February 26, 2026) Go Raw LLC is expanding its February 17, 2026, voluntary recall of a freeze-dried product to add two lots of select Quest Cat Food Chicken Recipe frozen products due to potentially low levels of thiamine (Vitamin B1).
The two lots of Quest Cat Food ChickeClinical Outcome Assessments (COA) Qualification Program Submissions
Clinical Outcome Assessments (COA) Qualification Program SubmissionsCovalent Medical – 695839 – 07/09/2025
Unapproved New Drugs/MisbrandedAnesthetic Vaporizer Recall: Draeger Removes Vapor 2000 and Vapor 3000 Vaporizers
Draeger is removing certain Vapor 2000 and Vapor 3000 Vaporizers due to impurities found within a component.